As Sanofi enters growth phase, Novartis exec Hudson to take the helm

Novartis has lost one executive from each of its Innovative Medicines units in the span of three days, now that Sanofi has named seasoned British sales and marketing executive Paul Hudson as the successor to CEO Olivier Brandicourt.

Sanofi will rely on Hudson's commercial chops as he inherits a business that has relied on recent launches from its specialty medicines unit to return to growth under Brandicourt, who is retiring after four years on the job...